Education
About Us
Working with TipRanks
Follow Us
Ani Pharmaceuticals (ANIP)
:ANIP
ANIP Stock Chart & Stats
$84.36
<$0.01(0.02%)
At close: 4:00 PM EST
$84.36
<$0.01(0.02%)
Day’s Range― - ―
52-Week Range$52.50 - $99.50
Previous CloseN/A
Volume18.69K
Average Volume (3M)439.69K
Market Cap
$1.90B
Enterprise Value$2.29B
Total Cash (Recent Filing)$262.61M
Total Debt (Recent Filing)$322.63M
Price to Earnings (P/E)51.7
Beta0.47
Next Earnings
Feb 26, 2026EPS Estimate
1.96Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.04
Shares Outstanding22,458,168
10 Day Avg. Volume521,419
30 Day Avg. Volume439,687
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)2.49
Price to Sales (P/S)1.74
P/FCF Ratio22.69
Enterprise Value/Market Cap1.21
Enterprise Value/Revenue2.77
Enterprise Value/Gross Profit4.75
Enterprise Value/Ebitda14.01
Forecast
1Y Price Target
$113.50Price Target Upside34.54% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Cortrophin Gel PerformanceCortrophin Gel continued to demonstrate strong performance, with revenues exceeding both FactSet consensus and analyst estimates.
Market PotentialThe addressable market for Cortrophin Gel is larger than previously modeled, offering significant growth opportunities.
Product Launch ImpactThe launch of the pre-filled syringe for Cortrophin Gel is resonating with both physicians and patients, contributing significantly to growth.
Bears Say
ILUVIEN Revenue ImpactILUVIEN reported net revenues were lower than anticipated, affected by continued reduced access among Medicare patients.
ANI Pharmaceuticals News
ANIP FAQ
What was Ani Pharmaceuticals’s price range in the past 12 months?
Ani Pharmaceuticals lowest stock price was $52.50 and its highest was $99.50 in the past 12 months.
What is Ani Pharmaceuticals’s market cap?
Ani Pharmaceuticals’s market cap is $1.90B.
When is Ani Pharmaceuticals’s upcoming earnings report date?
Ani Pharmaceuticals’s upcoming earnings report date is Feb 26, 2026 which is in 90 days.
How were Ani Pharmaceuticals’s earnings last quarter?
Ani Pharmaceuticals released its earnings results on Nov 10, 2025. The company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.77 by $0.27.
Is Ani Pharmaceuticals overvalued?
According to Wall Street analysts Ani Pharmaceuticals’s price is currently Undervalued.
Does Ani Pharmaceuticals pay dividends?
Ani Pharmaceuticals does not currently pay dividends.
What is Ani Pharmaceuticals’s EPS estimate?
Ani Pharmaceuticals’s EPS estimate is 1.96.
How many shares outstanding does Ani Pharmaceuticals have?
Ani Pharmaceuticals has 22,458,168 shares outstanding.
What happened to Ani Pharmaceuticals’s price movement after its last earnings report?
Ani Pharmaceuticals reported an EPS of $2.04 in its last earnings report, beating expectations of $1.77. Following the earnings report the stock price went down -1.659%.
Which hedge fund is a major shareholder of Ani Pharmaceuticals?
Currently, no hedge funds are holding shares in ANIP
ANI Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$113.50 (34.54% Upside)
$113.50 (34.54% Upside)
Blogger Sentiment
Bullish
ANIP Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 70.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.2%
Last 30 Days ▲ 6.2%
Last 30 Days ▲ 6.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
45.80%
12-Months-Change
Fundamentals
Return on Equity
7.83%
Trailing 12-Months
Asset Growth
9.38%
Trailing 12-Months
Company Description
Ani Pharmaceuticals
ANI Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. The company operates primarily in the areas of pain management, endocrinology, and cardiovascular health, offering a diverse portfolio that includes both established and innovative products. ANI Pharmaceuticals is dedicated to providing high-quality therapeutics that address unmet medical needs in various therapeutic segments.
ANIP Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a strong performance by ANI Pharmaceuticals, with record-breaking revenue and significant growth driven by the Rare Disease and Generics segments. Despite challenges in the ILUVIEN segment and Medicare funding affecting Retina products, the company raised its financial guidance and demonstrated robust cash flow and debt management.View all ANIP earnings summariesANIP Stock 12 Month Forecast
Average Price Target
$113.50
▲(34.54% Upside)
Technical Analysis
Avadel Pharmaceuticals
―
Pacira Pharmaceuticals
―
Supernus Pharmaceuticals
―
Amphastar Pharmaceuticals
―
Harrow Health
―
Ownership Overview
8.49% Insiders
19.82% Mutual Funds
22.46% Other Institutional Investors
29.45% Public Companies and
Individual Investors